Mangalam Organics Limited has released its comprehensive investor presentation for the third quarter ended December 31, 2025, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation was submitted to BSE Limited and The National Stock Exchange of India Limited on February 14, 2026.

Regulatory Compliance and Disclosure

The company, trading under scrip code 514418 on BSE and symbol MANORG on NSE, has made the investor presentation available on its website at www.mangalamorganics.com . Company Secretary and Compliance Officer Charmi Shah signed the regulatory filing, ensuring compliance with listing obligations.

Q3FY26 Financial Performance

The company's standalone operations showed mixed results for Q3FY26. Revenue from operations reached Rs 12,244.57 lakhs, representing a significant increase from Rs 10,052.72 lakhs reported in Q3FY25.

Consolidated Performance Highlights

The consolidated financial results showed robust performance with revenue from operations for Q3FY26 standing at Rs 16,429.84 lakhs versus Rs 12,391.66 lakhs in Q3FY25.

Business Operations and Strategic Focus

Mangalam Organics Limited operates as a pioneer in pine chemistry, manufacturing terpene and rosin derivatives. The company's product portfolio spans B2B operations including camphor, dipentene, and synthetic resins, alongside B2C retail operations under brands 'Mangalam' and 'CamPure'.

Corporate Structure and Compliance

The company operates with wholly owned subsidiaries including Mangalam Brands Private Limited, Mangalam Pooja Stores Private Limited, and Mangalam Speciality Chemicals Private Limited. The registered office and factory are located at Village Kumbhivali, Savroli-Kharpada Road, Khalapur-410 202, Dist. Raigad, Maharashtra.

Mangalam Organics witnessed significant institutional selling on Wednesday as multiple investors executed bulk deals worth over ₹1.60 crore. The microcap pharmaceutical stock saw prominent investor Vijay Kedia's investment firm among the key sellers, despite the stock posting gains during the trading session.

Major Bulk Deal Transactions

The bulk deal activity involved several institutional investors exiting their positions in the company:

Kedia Securities Private Limited, the investment firm of well-known investor Vijay Kedia, sold approximately 1.38 lakh shares worth ₹48.35 lakh, representing the largest single transaction among the bulk deals.

Stock Performance and Technical Indicators

Despite the institutional selling pressure, shares of Mangalam Drugs surged 5.00% during Wednesday's trading session to settle at ₹35.18 on the NSE. The stock has experienced significant volatility over different time periods, with contrasting performance trends.

The company's shares have declined 69.00% over the past 12 months, reflecting substantial erosion in market value. However, recent weeks have shown a recovery pattern, with the stock jumping nearly 40.00% over the past month, indicating renewed investor interest.

Technical Analysis Overview

The current market positioning shows mixed technical signals:

The stock is trading below both its 50-day and 200-day simple moving averages, suggesting the recent rally has not yet overcome longer-term resistance levels. The Money Flow Index around 90 indicates the counter is in a strongly overbought zone, as readings above 70 are typically considered overbought.

Financial Performance Update

The company's recent financial results reflect challenging operating conditions. For the quarter ended September 30, 2025, Mangalam Drugs reported a consolidated net loss of ₹7.40 crore, marking a significant deterioration from the profit after tax of ₹2.70 crore recorded in the corresponding quarter of the previous financial year.

Revenue performance also showed weakness, with total revenue declining to ₹50.00 crore in the quarter under review, representing a 38.00% decrease from ₹80.00 crore posted in the same quarter of the last financial year.

Company Background

Mangalam Drugs is a Gujarat-based pharmaceutical company that began manufacturing Active Pharmaceutical Ingredients and Intermediates in 1977. The company operates multi-product manufacturing facilities across two locations and maintains an in-house Research & Development laboratory to support its operations in the pharmaceutical sector.